%20--%3e%3csvg%20width='63.297821mm'%20height='39.29665mm'%20viewBox='0%200%2063.297821%2039.29665'%20version='1.1'%20id='svg8765'%20inkscape:version='1.1%20(c4e8f9ed74,%202021-05-24)'%20sodipodi:docname='OBALogoSingle2.svg'%20xmlns:inkscape='http://www.inkscape.org/namespaces/inkscape'%20xmlns:sodipodi='http://sodipodi.sourceforge.net/DTD/sodipodi-0.dtd'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:svg='http://www.w3.org/2000/svg'%3e%3csodipodi:namedview%20id='namedview8767'%20pagecolor='%23ffffff'%20bordercolor='%23666666'%20borderopacity='1.0'%20inkscape:pageshadow='2'%20inkscape:pageopacity='0.0'%20inkscape:pagecheckerboard='0'%20inkscape:document-units='mm'%20showgrid='false'%20fit-margin-top='0'%20fit-margin-left='0'%20fit-margin-right='0'%20fit-margin-bottom='0'%20inkscape:zoom='1.1759259'%20inkscape:cx='179.85827'%20inkscape:cy='102.04724'%20inkscape:window-width='1920'%20inkscape:window-height='972'%20inkscape:window-x='0'%20inkscape:window-y='27'%20inkscape:window-maximized='1'%20inkscape:current-layer='layer1'%20/%3e%3cdefs%20id='defs8762'%20/%3e%3cg%20inkscape:label='Layer%201'%20inkscape:groupmode='layer'%20id='layer1'%20transform='translate(-31.351095,-50.101677)'%3e%3cpath%20style='fill:none;stroke:%233584e4;stroke-width:3.965;stroke-linecap:square;stroke-linejoin:round;stroke-miterlimit:4;stroke-dasharray:none;stroke-opacity:1'%20d='m%2077.07508,77.78787%2014.84134,8.87817%20V%2052.83397%20L%2034.08359,86.5521%20V%2053.69366%20l%2015.27351,9.31107'%20id='path8388'%20sodipodi:nodetypes='cccccc'%20/%3e%3c/g%3e%3c/svg%3e)
#healthcare
Stock analysis posts tagged "healthcare" from Openbook.
Johnson and Johnson Stock Analysis: What the Latest JNJ Results Mean for Investors
J&J beat on adjusted EPS and raised full-year guidance, yet the shares closed 5.73% lower at $248.61. MedTech growth of just 2.5% is the reason.
UnitedHealth Group (UNH) Fundamentals: Insurance and Care Delivery
This UnitedHealth stock analysis breaks down the Q2 2026 numbers, the medical care ratio, and how the Optum and UnitedHealthcare margins moved.
How Merck (MRK) Makes Its Money: Oncology and Vaccine Fundamentals
A Merck stock analysis of where MRK earns its revenue across oncology, vaccines and animal health, and what the 2028 Keytruda patent expiry changes.
Medtronic Grew 13.7%. An Extra Week Supplied Half of It
Medtronic's 13.7% organic quarter included about 670bp from a 53rd fiscal week. The underlying rate is near 7%, and that is still the story.
Smith+Nephew After the CFO Exit: What the Turnaround Numbers Say
Smith+Nephew fell 3.5% when its CFO quit for Baxter. The turnaround numbers underneath are better than the revenue line suggests — and unfinished.
Moderna (MRNA) Stock Analysis: The Melanoma Data and the Numbers
A Moderna stock analysis after the 177 percent move: what the INTerpath-001 melanoma readout disclosed, Q2 2026 revenue and losses, and the cash runway.
Inside AbbVie (ABBV) Shares: Immunology, Neuroscience and Botox
This AbbVie stock analysis breaks down Q2 2026 results, the Skyrizi and Rinvoq franchises that replaced Humira, margins, the dividend and key risks.